No association between polygenic risk scores for cancer and development of radiotherapy toxicity
Name:
35840111.pdf
Size:
1.030Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Barnett, G. C.Kerns, S. L.
Dorling, L.
Fachal, L.
Aguado-Barrera, M. E.
Martínez-Calvo, L.
Jandu, H. K.
Welsh, C.
Tyrer, J.
Coles, C. E.
Haviland, J. S.
Parker, C.
Gómez-Caamaño, A.
Calvo-Crespo, P.
Sosa-Fajardo, P.
Burnet, Neil G
Summersgill, Holly
Webb, A.
De Ruysscher, D.
Seibold, P.
Chang-Claude, J.
Talbot, C. J.
Rattay, T.
Parliament, M.
De Ruyck, K.
Rosenstein, B. S.
Pharoah, P. D. P.
Dunning, A. M.
Vega, A.
West, Catharine M L
Affiliation
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UKIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: To test whether updated polygenic risk scores (PRS) for susceptibility to cancer affect risk of radiotherapy toxicity. Experimental design: Analyses included 9,717 patients with breast (n=3,078), prostate (n=5,748) or lung (n=891) cancer from XXXX and XXXX Consortia cohorts. Patients underwent potentially curative radiotherapy and were assessed prospectively for toxicity. Germline genotyping involved genome-wide single nucleotide polymorphism (SNP) arrays with non-typed SNPs imputed. PRS for each cancer were generated by summing literature-identified cancer susceptibility risk alleles: 352 breast, 136 prostate, 24 lung. Weighted PRS were generated using log odds ratios for cancer susceptibility. Standardized total average toxicity (STAT) scores at 2 and 5 years (breast, prostate) or 6 to 12 months (lung) quantified toxicity. Primary analysis tested late STAT, secondary analyses investigated acute STAT, and individual endpoints and SNPs using multivariable regression. Results: Increasing PRS did not increase risk of late toxicity in patients with breast (OR 1.000, 95%CI 0.997-1.002), prostate (OR 0.99, 95%CI 0.98-1.00; weighted PRS OR 0.93, 95%CI 0.83-1.03) or lung (OR 0.93, 95%CI 0.87-1.00; weighted PRS OR 0.68, 95%CI 0.45-1.03) cancer. Similar results were seen for acute toxicity. Secondary analyses identified rs138944387 associated with breast pain (OR=3.05; 95%CI 1.86- 5.01; P=1.09 × 10-5) and rs17513613 with breast oedema (OR=0.94; 95%CI 0.92- 0.97; P=1.08 × 1 0-5). Conclusions: Patients with increased polygenic predisposition to breast, prostate or lung cancer can safely undergo radiotherapy with no anticipated excess toxicity risk. Some individual SNPs increase likelihood of a specific toxicity endpoint warranting validation in independent cohorts and functional studies to elucidate biologic mechanisms.Citation
Barnett GC, Kerns SL, Dorling L, Fachal L, Aguado-Barrera ME, Martínez-Calvo L, et al. No association between polygenic risk scores for cancer and development of radiotherapy toxicity. International journal of radiation oncology, biology, physics. 2022 Jul 12. PubMed PMID: 35840111. Epub 2022/07/16. eng.Journal
International Journal of Radiation Oncology Biology PhysicsDOI
10.1016/j.ijrobp.2022.06.098PubMed ID
35840111Additional Links
https://dx.doi.org/10.1016/j.ijrobp.2022.06.098Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2022.06.098
Scopus Count
Collections
Related articles
- Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
- Authors: Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, West CM
- Issue date: 2016 Mar 15
- Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
- Authors: Ahmed M, Dorling L, Kerns S, Fachal L, Elliott R, Partliament M, Rosenstein BS, Vega A, Gómez-Caamaño A, Barnett G, Dearnaley DP, Hall E, Sydes M, Burnet N, Pharoah PD, Eeles R, West CM
- Issue date: 2016 May 10
- Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
- Authors: Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM
- Issue date: 2012 Jan
- XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.
- Authors: Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, Yarnold J, Talbot CJ, Imai T, Azria D, Koch CA, Dunning AM, Burnet N, Bliss JM, Symonds RP, Rattay T, Suga T, Kerns SL, Bourgier C, Vallis KA, Sautter-Bihl ML, Claßen J, Debus J, Schnabel T, Rosenstein BS, Wenz F, West CM, Popanda O, Chang-Claude J
- Issue date: 2015 Aug 1
- A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
- Authors: Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM
- Issue date: 2014 May